Younger patients with a specific form of myositis associated with antibodies to a protein called HMGCR have a worse prognosis than older patients.
Medical record review of patients admitted to the Johns Hopkins Hospital over 20-years, revealed that pneumocystis jiroveci pneumonia infection is a rare but persistent risk for patients with rheumatic diseases.
Dr. Myma Albayda with the Johns Hopkins Arthritis Center highlights what’s involved in a joint injection.
In this issue of LEAP you can read about our precision approach to an increasingly common illness, gout, to a rare illness linked to Sjögren’s, and to cancer patients who are developing some autoimmune-mediated complications. And we are especially excited to share with you a tremendous breakthrough in understanding how rheumatoid arthritis begins.
The study provides new evidence that a bacterium known to cause chronic inflammatory gum infections also triggers the inflammatory autoimmune response characteristic of chronic, joint-destroying rheumatoid arthritis (RA). The new findings have important implications for prevention and treatment of RA.
A new biomarker discovered using cutting-edge technologies is found in people who develop scleroderma and cancer within a short period of time.
Vaccines have been scientifically proven to save lives, increase lifespans, and maintain quality of life. Currently, only 39% of adults receive an annual flu shot. There are specific steps that can be taken to improve the vaccination rate. This is especially important in the immuno-compromised population.
On Saturday October 15, 2016, the Hopkins Rheumatology CARES (Centers Advancing RESearch) team was out in full force to support the “Myositis Run, Walk, n’ Roll 5k” event at Centennial Park in Columbia, MD.
This study explored the relationship between subtypes of demyelinating disorders and Sjogren’s syndrome. These findings help identify the spectrum of neurological disease directly attributable to SS.